SpectraCell Laboratories has added HS-Omega-3 Index test that measures the amount of two fatty acids called EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in a person's red blood cells to its test menu.
Red blood cell fatty acid composition reflects long-term intake of EPA and DHA, and are also highly correlated with the amount of fatty acids found in heart tissue. The higher the content of the fatty acids, EPA and DHA, the lower the risk of a fatal heart attack.
SpectraCell said that the research shows that the Omega 3 Index is predictive of cardiovascular disease, and especially predictive of sudden death caused by a heart attack. Since the first symptom of heart disease is often a fatal heart attack, the Omega 3 Index has profound implications. When the Omega 3 Index is high (above 8%), there is an astounding 90% reduction in risk of sudden death, whereas an index less than 4% has highest level of risk.
The Omega 3 Index will also helps a person to test the ratio of omega-6 to omega-3 fatty acids in their body. Omega 6 fatty acids contribute to the inflammation while omega 3 fatty acids reduce whole body inflammation. Our Paleolithic ancestors, who were completely free of degenerative diseases like heart disease, arthritis and dementia, maintained an omega 6 to omega 3 ratio around 2:1.
Fred Crawford, vice president of operations and laboratory director for SpectraCell, said: “So many people are taking fish oils or omega-3 fatty acid supplements nowadays. People want to know if these supplements are being absorbed and utilized by their body efficiently, or if they are taking the correct dosage. This test finally allows a person to monitor their omega 3 status.”
SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing with micronutrient testing and the Lipoprotein Particle Profile (LPP).